Global Glaucoma Therapeutics Market to Reach $7.2 Billion by 2030

New York, April 14, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Glaucoma Therapeutics Industry" - https://www.reportlinker.com/p06044625/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Glaucoma Therapeutics Market to Reach $7.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Glaucoma Therapeutics estimated at US$5.5 Billion in the year 2022, is projected to reach a revised size of US$7.2 Billion by 2030, growing at aCAGR of 3.5% over the period 2022-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is projected to record 3.2% CAGR and reach US$2.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Combination Drugs segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 5.5% CAGR

The Glaucoma Therapeutics market in the U.S. is estimated at US$1.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 5.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Select Competitors (Total 44 Featured)
- Aerie Pharmaceuticals, Inc.
- Allergan, Inc.
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Santen Pharmaceutical Co., Ltd.
- Valeant Pharmaceuticals International, Inc.


Read the full report: https://www.reportlinker.com/p06044625/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Glaucoma Therapeutics - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Glaucoma Therapeutics Market Analysis of Annual
Sales in US$ Million for Years 2014 through 2030

Table 2: World Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 3: World Historic Review for Glaucoma Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 4: World 16-Year Perspective for Glaucoma Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 5: World Recent Past, Current & Future Analysis for
Prostaglandins Analogs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 6: World Historic Review for Prostaglandins Analogs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 7: World 16-Year Perspective for Prostaglandins Analogs
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 8: World Recent Past, Current & Future Analysis for
Combination Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 9: World Historic Review for Combination Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 10: World 16-Year Perspective for Combination Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 11: World Recent Past, Current & Future Analysis for Beta
Blockers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 12: World Historic Review for Beta Blockers by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 13: World 16-Year Perspective for Beta Blockers by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 14: World Recent Past, Current & Future Analysis for
Alpha Adrenergic Agonists by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 15: World Historic Review for Alpha Adrenergic Agonists
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 16: World 16-Year Perspective for Alpha Adrenergic
Agonists by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 17: World Recent Past, Current & Future Analysis for
Carbonic Anhydrase Inhibitors by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 18: World Historic Review for Carbonic Anhydrase
Inhibitors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2014 through 2021 and % CAGR

Table 19: World 16-Year Perspective for Carbonic Anhydrase
Inhibitors by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 20: World Recent Past, Current & Future Analysis for
Other Drug Classes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 21: World Historic Review for Other Drug Classes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 22: World 16-Year Perspective for Other Drug Classes by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 23: World Recent Past, Current & Future Analysis for
Hospital Pharmacies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 24: World Historic Review for Hospital Pharmacies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 25: World 16-Year Perspective for Hospital Pharmacies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 26: World Recent Past, Current & Future Analysis for
Retail Pharmacies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 27: World Historic Review for Retail Pharmacies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 28: World 16-Year Perspective for Retail Pharmacies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 29: World Recent Past, Current & Future Analysis for
Online by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 30: World Historic Review for Online by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 31: World 16-Year Perspective for Online by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

UNITED STATES
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 32: USA Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 33: USA Historic Review for Glaucoma Therapeutics by Drug
Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 34: USA 16-Year Perspective for Glaucoma Therapeutics by
Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 35: USA Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 36: USA Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 37: USA 16-Year Perspective for Glaucoma Therapeutics by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Retail Pharmacies and Online for the Years
2014, 2023 & 2030

CANADA
Table 38: Canada Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 39: Canada Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 40: Canada 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 41: Canada Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 42: Canada Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 43: Canada 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

JAPAN
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 44: Japan Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 45: Japan Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 46: Japan 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 47: Japan Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 48: Japan Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 49: Japan 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

CHINA
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 50: China Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 51: China Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 52: China 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 53: China Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 54: China Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 55: China 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

EUROPE
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 56: Europe Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 57: Europe Historic Review for Glaucoma Therapeutics by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 58: Europe 16-Year Perspective for Glaucoma Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030

Table 59: Europe Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 60: Europe Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 61: Europe 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 62: Europe Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 63: Europe Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 64: Europe 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

FRANCE
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 65: France Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 66: France Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 67: France 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 68: France Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 69: France Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 70: France 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

GERMANY
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 71: Germany Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 72: Germany Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 73: Germany 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 74: Germany Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 75: Germany Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 76: Germany 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

ITALY
Table 77: Italy Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 78: Italy Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 79: Italy 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 80: Italy Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 81: Italy Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 82: Italy 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

UNITED KINGDOM
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 83: UK Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 84: UK Historic Review for Glaucoma Therapeutics by Drug
Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 85: UK 16-Year Perspective for Glaucoma Therapeutics by
Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 86: UK Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 87: UK Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 88: UK 16-Year Perspective for Glaucoma Therapeutics by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospital Pharmacies, Retail Pharmacies and Online for the Years
2014, 2023 & 2030

SPAIN
Table 89: Spain Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 90: Spain Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 91: Spain 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 92: Spain Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 93: Spain Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 94: Spain 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

RUSSIA
Table 95: Russia Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 96: Russia Historic Review for Glaucoma Therapeutics by
Drug Class - Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 97: Russia 16-Year Perspective for Glaucoma Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes for the Years 2014, 2023 & 2030

Table 98: Russia Recent Past, Current & Future Analysis for
Glaucoma Therapeutics by Distribution Channel - Hospital
Pharmacies, Retail Pharmacies and Online - Independent Analysis
of Annual Sales in US$ Million for the Years 2022 through 2030
and % CAGR

Table 99: Russia Historic Review for Glaucoma Therapeutics by
Distribution Channel - Hospital Pharmacies, Retail Pharmacies
and Online Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 100: Russia 16-Year Perspective for Glaucoma Therapeutics
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospital Pharmacies, Retail Pharmacies and Online for the
Years 2014, 2023 & 2030

REST OF EUROPE
Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Glaucoma Therapeutics by Drug Class -
Prostaglandins Analogs, Combination Drugs, Beta Blockers, Alpha
Adrenergic Agonists, Carbonic Anhydrase Inhibitors and Other
Drug Classes - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for Glaucoma
Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 103: Rest of Europe 16-Year Perspective for Glaucoma
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Prostaglandins Analogs, Combination Drugs, Beta
Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase
Inhibitors and Other Drug Classes for the Years 2014, 2023 &
2030

Table 104: Rest of Europe Recent Past, Current & Future
Analysis for Glaucoma Therapeutics by Distribution Channel -
Hospital Pharmacies, Retail Pharmacies and Online - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 105: Rest of Europe Historic Review for Glaucoma
Therapeutics by Distribution Channel - Hospital Pharmacies,
Retail Pharmacies and Online Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 106: Rest of Europe 16-Year Perspective for Glaucoma
Therapeutics by Distribution Channel - Percentage Breakdown of
Value Sales for Hospital Pharmacies, Retail Pharmacies and
Online for the Years 2014, 2023 & 2030

ASIA-PACIFIC
Glaucoma Therapeutics Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for Glaucoma Therapeutics by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 108: Asia-Pacific Historic Review for Glaucoma
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 109: Asia-Pacific 16-Year Perspective for Glaucoma
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2014, 2023 & 2030

Table 110: Asia-Pacific Recent Past, Current & Future Analysis
for Glaucoma Therapeutics by Drug Class - Prostaglandins
Analogs, Combination Drugs, Beta Blockers, Alpha Adrenergic
Agonists, Carbonic Anhydrase Inhibitors and Other Drug Classes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 111: Asia-Pacific Historic Review for Glaucoma
Therapeutics by Drug Class - Prostaglandins Analogs,
Combination Drugs, Beta Blockers, Alpha Adrenergic Agonists,
Carbonic Anhydrase Inhibitors and Other Drug Classes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 112: Asia-Pacific 16-Year Perspective for Glaucoma
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Prostaglandins Analogs, Combination Drugs, Beta

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06044625/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

              Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001